Independent equity research
Is Johnson & Johnson (JNJ) a Buy, Hold or Sell?
Johnson & Johnson — our independent, AI-built valuation and rating, in brief.
HOLD
12-mo fair value
$258.00
To fair value
−2%
Report dated 2026-07-24 · fair value derived independently of the market price.
The thesis, in brief
HOLD/$258 (~spot) on Q2 2026. Superb (Innov Medicine+MedTech) but re-rated to 99th-pctile ~22x fwd, DCF below spot (beta 0.235 trap); talc unresolved
How we value it
We value Johnson & Johnson using P/E + FCF/DCF (adj EPS). The 12-month fair value is set from that intrinsic estimate first, then compared to the market to read the upside or downside — never anchored to the current price.
What the full report covers
- Business & moat + industry cycle
- Earnings quality & normalized EPS
- Returns on capital (ROIC vs WACC)
- Balance-sheet safety
- Two independent valuations (DCF + multiples)
- Bear / base / bull fair values
- Earnings-call analysis
- Insider activity & positioning
- Technicals (RSI / ADX)
- A falsifiable thesis
Read the full Johnson & Johnson report
The complete model, the scenarios, and every number behind the call — plus 38 other names. One subscription, cancel anytime.